Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation.
By H. Bartelink, J. Horiot, P. Poortmans, H. Struikmans, W. van den Bogaert, I. Barillot, A. Fourquet, J. Borger, J. Jager, W. Hoogenraad and 2 more. New England Journal of Medicine, 2001
976 citations recorded by the source corpus.
Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/4294f9ed8d560b0643a3b228e66d0fd5e2028c6c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- N. Almansour
- A. Stanisławek
- Marcin Czeczelewski
- Sergiusz Łukasiewicz
- Robert Sitarz
- J. Baj
- Alicja Forma
In Pathology and Forensic Medicine
Citations in the corpus
- Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review (2021, background): “showed that additional radiation (16 Gy) to the tumor bed combined with standard radiotherapy might decrease the risk of local recurrence [72].”
- Advances in Radiation Therapy: Conventional to 3D, to IMRT, to 4D, and Beyond (2005, background): “Until recently, the total time and dose of standard radiation had not significantly changed in over 20 years with the exception of a possible 10 to 16 Gy electron boost to the surgical cavity.(83,84) Nagging questions persisted, driving current clinical research into a new era, particularly for wome”
- A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. (2008, methodology): “An additional boost dose of 16 Gy was used at the discretion of the radiation oncologist in accordance with the results of the European Organisation for Research and Treatment of Cancer (EORTC) randomized clinical trial.(9) Given that the breast size and the total dose were factors associated with i”
- Physical activity and survival after breast cancer diagnosis. (2004, result): “The numbers of cases of recurrent breast cancer calculated in this manner are similar to the numbers expected given the recurrence rates found in a large (N=5569) trial of early stage breast cancer.(28)”
- Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. (2005, background): “A boost may be particularly useful in premenopausal patients [145].”
- Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence (2022, background): “Radiotherapy in patients with a family history of breast cancer is considered to be at a higher risk (Bartelink et al., 2001).”